Notice: eScholarship will undergo scheduled maintenance from Tuesday, January 21 to Wednesday, January 22. Some functionality may not be available during this time. Learn more at eScholarship Support.
A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57)
